We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Nanoprobes Visualize Tumors Through Skin

By Biotechdaily staff writers
Posted on 17 Feb 2005
Nano-sized particles entrenched with bright, light-emitting molecules have helped scientists see tumors more than 1 cm below the skin surface utilizing only infrared light. More...


A group of investigators from the University of Pennsylvania (Penn, Philadelphia, PA, USA) and the University of Minnesota (Minneapolis-St. Paul, MN, USA) has embedded fluorescent substances called porphyrins within the surface of a polymersome, a cell-like vesicle, to image a tumor within a live laboratory rat. Their findings were published in the February 7, 2005, issue of the journal [U.S.] National Academy of Science.

"We have shown that the dispersion of thousands of brightly emissive multi-porphyrin fluorophores within the polymersome membrane can be used to optically image tissue structures deep below the skin--with the potential to go even deeper,” remarked Dr. Michael J. Therien, a professor of chemistry at Penn. "It should also be possible to use an emissive polymersome vesicle to transport therapeutics directly to a tumor, enabling us to actually see if chemotherapy is really going to its intended target.”

Polymersomes work like the bilayered membranes of living cells. While cell membranes are created from a double layer of fatty phospholipid chains, a polymersome is made up of two layers of synthetic co-polymers. Similar to a living cell, the polymers' own membrane has a hydrophobic core. This research demonstrates that the fluorophores uniformly disperse within this core, generating a nanometer-sized, light-emitting structure.

The investigators showed in the study how they can utilize these emissive polymersomes to target markers on the surface of a certain kind of tumor cell. When exposed to near-infrared light, which can move through tissue, the fluorophores within the polymersome react with a bright near-infrared signal that can then be detected.

There is growing interest in developing new technology that will enable optical imaging of cancerous tissue, providing applications that cost less and are more accessible than magnetic resonance imaging (MRI)-based techniques, and without debilitating side effects associated with radioactivity, according to Dr. Therien. With this new imaging technique, the fluorophores can also be triggered to respond to different wavelengths of near-infrared light. This creates a setting for using emissive polymersomes to target a host of cancer cell-surface markers in the body simultaneously.



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
Immunofluorescence Analyzer
IFA System
New
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Alzheimer’s pathology can start 15 to 20 years before symptoms, and validated tools that reach patients earlier help pave the way for earlier detection. (Image Credit: Adobe Stock)

Alzheimer’s Blood Test Becomes First FDA-Cleared Option for Adults as Young as 40

C2N Diagnostics’ PrecivityAD2 blood test was cleared by the U.S. Food and Drug Administration (FDA) on August 20, 2026, for adults as young as 40 who are experiencing signs of cognitive impairment, according... Read more

Pathology

view channel
Image: Adrenal gland tumor stained with hematoxylin and eosin (top) and CYP11B2 (bottom) (Photo courtesy of Christofer Juhlin)

Simple Immunohistochemical Size Ratio Improves Classification of Primary Aldosteronism

Primary aldosteronism is a common but underdiagnosed cause of hypertension, in which excess aldosterone promotes salt retention and raises blood pressure. Identifying the dominant source of hormone overproduction... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.